Coherus BioSciences   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Redwood City CA United States (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2014
NCT02115750
First Marketed Drug
2018
Filgrastim (neupogen)
First NDA Approval
2023
toripalimab (LOQTORZ)
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Coherus Biosciences, Inc. | Coherus BioSciences, Inc. | COHERUS BIOSCIENCES INC | Coherus BioSciences (parent company for Zao InteKrin)

Active Ingredients

Marketed Drugs (4)

adalimumab (humira) (2021)

Filgrastim (neupogen) (2018)

ranibizumab (lucentis) (2022)

toripalimab (LOQTORZ) (2023 NDA)

Drugs in Phase 3 Trials (2)

adalimumab (humira) (1 trial)

etanercept (enbrel) (3 trials)

Drugs in Phase 2 Trials (10)

Key: Coherus BioSciences (2) Acquired (8)

atezolizumab (Tecentriq) (1 trial)

bevacizumab (avastin) (1 trial)

js006 (1 trial)

pioglitazone (actos) (1 trial)

srf114 (1 trial)

srf388 (2 trials)

srf617 (2 trials)

t131 (3 trials)

toripalimab (LOQTORZ) (1 trial)

zimberelimab (1 trial)

Drugs in Phase 1 Trials (2)

Key: Coherus BioSciences (1) Acquired (1)

Filgrastim (neupogen) (3 trials)

srf231 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Psoriasis (Phase 3)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 14